Axogen, Inc. (AXGN)
NASDAQ: AXGN · Real-Time Price · USD
34.00
-0.11 (-0.32%)
Jan 29, 2026, 1:50 PM EST - Market open
Axogen Employees
As of December 31, 2024, Axogen had 452 total employees, including 451 full-time and 1 part-time employees. The number of employees increased by 24 or 5.61% compared to the previous year.
Employees
452
Change (1Y)
24
Growth (1Y)
5.61%
Revenue / Employee
$475,020
Profits / Employee
-$4,639
Market Cap
1.70B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 452 | 24 | 5.61% | 451 | 1 |
| Dec 31, 2023 | 428 | 32 | 8.08% | 426 | 2 |
| Dec 31, 2022 | 396 | -55 | -12.20% | 394 | 2 |
| Dec 31, 2021 | 451 | 83 | 22.55% | 428 | 23 |
| Dec 31, 2020 | 368 | -26 | -6.60% | 346 | 22 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AdaptHealth | 10,500 |
| Enovis | 7,367 |
| QuidelOrtho | 6,600 |
| UFP Technologies | 4,146 |
| Tandem Diabetes Care | 2,650 |
| Artivion | 1,600 |
| NovoCure | 1,488 |
| Establishment Labs Holdings | 1,023 |
AXGN News
- 7 days ago - Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock - GlobeNewsWire
- 7 days ago - Axogen Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 13 days ago - Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 17 days ago - Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 - GlobeNewsWire
- 2 months ago - Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) - GlobeNewsWire
- 2 months ago - FDA approves Axogen's nerve repair graft - Reuters
- 2 months ago - Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen - Seeking Alpha
- 3 months ago - Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors - Seeking Alpha